Clinical trial NCT05394610: Effectiveness of the Sana Device on Fibromyalgia Symptoms
Official title: A Confirmatory Investigation of the Effectiveness of Sana Treatment in Fibromyalgia
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Fibromyalgia
Pain, Chronic
Quality of Life
Lead sponsor: Sana Health
Sponsor class: INDUSTRY
Collaborators: name: University of Pennsylvania
First posted: 2022-05-27
Enrollment: 166
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Double blind sham contolled
Primary purpose: TREATMENT

Brief summary: This is study designed to confirm the effectiveness of the Sana Device in patients with pain due to fibromyalgia on quality of life as measured by the Fibromyalgia Impact Questionnaire Revised (FIQR). It is a two arm study in which subjects will be randomly assigned to either active device group or sham-controlled group.


Eligibility criteria: Inclusion Criteria:

* Willing to and capable of providing written informed consent prior to the conduct of any study-related procedures.
* Male or female, 18 to 65 years of age, inclusive.
* Have a history of experiencing fibromyalgia - like symptoms for a minimum of 36 months (3 years) prior to Screening.
* Subject must be in good physical health based on physical exams, vitals, and/or self-reporting. For subjects where there may not be sufficient recent medical records to document general good health the participant will be asked to self-report at the investigator's discretion.
* Any analgesic medications and medication dosages must be at approximately stable levels for at least 8 weeks prior to enrollment and remain steady throughout the study.
* A total score on the Generalized Anxiety Disorder 7-item scale (GAD-7) of 5 or above.
* A total score on the Patient Health Questionnaire 8-item (PHQ-8) of 5 or above.
* A total score on the STOP-Bang questionnaire of 3 or below.
* Willing and able to comply with the study requirements, complete study assessments, and participate at scheduled times for the duration of the Treatment Phase.
* Able to understand, speak and read English sufficient for the completion of study assessments.

Exclusion Criteria:

* Pregnant or lactating females as self-reported.
* History or presence of photo-sensitive epilepsy or other photo-sensitive conditions.
* History or presence of condition(s) that may affect balance, such as seizure disorders or vertigo.
* History of presence of condition (s) that meet the criteria for major depressive disorder (MDD), bipolar disorder, or any other personality disorders, at the discretion of the investigator.
* Presence of cancer pain, acute pain following injury or other severe pain not primarily associated with fibromyalgia, at discretion of the investigator.
* Surgery or trauma requiring rehabilitation within the last 12 weeks.
* Vision impairments that affect perception of light, color, or brightness in one or both eyes, and differences in visual perception between eyes.
* Deafness in one or both ears, perceived differences in hearing between ears, or tinnitus.
* Current ear or eye infection, untreated allergies, or acute illness that may affect eyes or hearing (e.g., due to congestion).
* Presence of inflammation or broken skin around the eyes in the area of the mask.
* Presence of narcolepsy or untreated sleep apnea or requiring treatment for sleep apnea such that use of device at bedtime will be interrupted, at discretion of the investigator.
* At the discretion of the Investigator, participation in any other clinical study in which medication(s) are being delivered or have used an investigational drug or device within the last 30 days.
* Any pending legal action that could prohibit participation or compliance in the study.
* Recent history of or current evidence of suicidal ideation or active suicidal behavior, based on medical history, at the discretion of the investigator.
* Significant medical conditions or other circumstances which, in the opinion of the investigator, would preclude compliance with the protocol, adequate cooperation in the study or obtaining informed consent, or may prevent the subject from safely participating in study.
* Employment by the investigator or the study site, with direct involvement in the proposed study or other studies under the direction of the investigator or study site, or a family member of an employee or of the investigator.

Primary outcomes:
measure: Change in Fibromyalgia Symptoms
timeFrame: 6 weeks
Secondary outcomes:
measure: Changes in Generalized Anxiety Symptoms
timeFrame: 6 weeks
measure: Changes in Depression Symptoms
timeFrame: 6 weeks
measure: Changes in Sleep Quality
timeFrame: 6 weeks
measure: Changes in Pain
timeFrame: 6 weeks
measure: Perceived Change in Quality of Life
timeFrame: 6 weeks
Other outcomes:
Locations:
Study officials:
affiliation: University of Pennsylvania
name: Martin Cheatle, PhD
role: PRINCIPAL_INVESTIGATOR
References: